Pharmacokinetic Profile of Orally Administered Scyllo‐Inositol (Elnd005) in Plasma, Cerebrospinal Fluid and Brain, and Corresponding Effect on Amyloid‐Beta in Healthy Subjects. Issue 2 (16th March 2013)

• Record Type: Journal Article
• Authors: Liang, Earvin; Garzone, Pamela; Cedarbaum, Jesse M.; Koller, Martin; Tran, Thao; Xu, Victor; Ross, Brian; Jhee, Stanford S.; Ereshefsky, Larry; Pastrak, Aleksandra; Abushakra, Susan
• Is Part Of: Clinical pharmacology in drug development. Volume 2:Issue 2(2013:Apr.)
• Page Start: 186
• Page End: 194
• Publication Date: 2013-03-16
• Subjects: Drugs -- Testing -- Periodicals; Drug development -- Periodicals; Clinical pharmacology -- Periodicals; 615.580724
• DOI: 10.1002/cpdd.14
• Languages: English
• ISSNs: 2160-7648

Abstract

<abstract abstract-type="main" xml:lang="en"> <title>Abstract</title> <sec id="cpdd14-sec-0001" sec-type="section"> <p>ELND005 (scyllo‐inositol), an endogenous inositol stereoisomer, is being investigated as an oral treatment for Alzheimer's disease (AD). Pharmacokinetics of ELND005 in plasma, cerebrospinal fluid (CSF), and brain was characterized in healthy young subjects. Eight men received 2000 mg ELND005 every 12 hours for 10 days. Plasma and CSF samples were collected at predetermined time points; ELND005 and amyloid‐beta (Aβ) fragments were measured by validated bioanalytical methods. Brain ELND005 levels, estimated by ¹H Magnetic Resonance Spectroscopy (MRS) scans were obtained from gray/white matter voxels at baseline and Day 8. ELND005 was well‐tolerated during the study. During the apparent steady state, ELND005 plasma levels rapidly peaked at 39.8 µg/mL and decreased to an average trough concentration of 10.6 µg/mL at the end of the 12‐hour dosing regimen. In contrast, CSF drug levels slowly peaked at 13.7 µg/mL and remained near the same level with average trough concentrations of 12.4 µg/mL. At Day 8, Brain ELND005 concentrations increased by 58–76% compared to baseline levels. The CSF concentrations achieved in this study were similar to those associated with efficacy in transgenic models of AD. No changes were detected in plasma and CSF levels of Aβ fragments.</p> </sec> </abstract>